KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Cash Flow: 2014-2024

Historic Net Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$91.3 million.

  • CRISPR Therapeutics AG's Net Cash Flow rose 135.89% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 120.10%. This contributed to the annual value of -$91.3 million for FY2024, which is 151.58% down from last year.
  • According to the latest figures from FY2024, CRISPR Therapeutics AG's Net Cash Flow is -$91.3 million, which was down 151.58% from $176.9 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year Net Cash Flow high stood at $236.6 million for FY2020, and its period low was -$715.8 million during FY2022.
  • For the 3-year period, CRISPR Therapeutics AG's Net Cash Flow averaged around -$210.0 million, with its median value being -$91.3 million (2024).
  • In the last 5 years, CRISPR Therapeutics AG's Net Cash Flow plummeted by 203.76% in 2021 and then surged by 124.72% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Net Cash Flow (Yearly) stood at $236.6 million in 2020, then tumbled by 203.76% to -$245.5 million in 2021, then tumbled by 191.55% to -$715.8 million in 2022, then soared by 124.72% to $176.9 million in 2023, then plummeted by 151.58% to -$91.3 million in 2024.